Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 236-631-5 | CAS number: 13453-69-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Justification for type of information:
- A toxicokinetic assessment was performed based on data available for dilithium tetraborate. Based on the physical/chemical properties of dilithium tetraborate, absorption factors for this substance are derived to be 100% (oral), 100% (inhalation of aqueous aerosols) and 0.5% (dermal absorption from aqueous solutions) for risk assessment purposes. The bioaccumulation potential is expected to be low.
As lithium metaborate has similar physicochemical properties ie. low vapour pressure and soluble in water then it is expected that the toxicokinetics assessment would be similar if not identical for lithium metaborate especially since all absorption factors derived were based on evidence for boric compounds such as boric acid. Both the inorganic borates, lithium metaborate and dilithium tetraborate, will be converted to boric acid at physiological pH in the aqueous layer on the surfaces of the mucosa. Boric acid is known to be readily taken up from the gastrointestinal tract in rats and humans, as demonstrated by experimental evidence in both human and animal studies, where more than 90% of the administered dose of borate was excreted as boric acid.
Sufficient evidence therefore exists to propose the same absorption factors for the toxicokinetics assessment. Read-across to dilithium tetraborate is proposed.
Data source
Materials and methods
Test material
- Reference substance name:
- Lithium metaborate
- EC Number:
- 236-631-5
- EC Name:
- Lithium metaborate
- Cas Number:
- 13453-69-5
- Molecular formula:
- BHO2.Li
- IUPAC Name:
- lithium metaborate
Constituent 1
Results and discussion
Applicant's summary and conclusion
- Conclusions:
- A toxicokinetics assessment was performed using the available data for diltihium tetraborate. Lithium metaborate is sufficiently similar in terms of physicochemical properties and behaviour upon absorption that the same absorption factors can be used.
- Executive summary:
A toxicokinetic assessment was performed based on the available data of dilithium tetraborate. Based on the physical/chemical properties of dilithium tetraborate, absorption factors for this substance are derived to be 100% (oral), 100% (inhalation of aqueous aerosols) and 0.5 % (dermal absorption from aqueous solutions) for risk assessment purposes. The bioaccumulation potential is expected to be low.
As lithium metaborate has similar physicochemical properties ie. low vapour pressure and soluble in water then it is expected that the toxicokinetics assessment would be similar if not identical for lithium metaborate especially since all absorption factors derived were based on evidence for boric compounds such as boric acid. Both the inorganic borates, lithium metaborate and dilithium tetraborate, will be converted to boric acid at physiological pH in the aqueous layer on the surfaces of the mucosa. Boric acid is known to be readily taken up from the gastrointestinal tract in rats and humans, as demonstrated by experimental evidence in both human and animal studies, where more than 90% of the administered dose of borate was excreted as boric acid.
Sufficient evidence therefore exists to propose the same absorption factors for lithium metaborate of 100% (oral), 100% (inhalation of aqueous aerosols) and 0.5 % (dermal absorption from aqueous solutions) for risk assessment purposes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.